JP2007528417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007528417A5 JP2007528417A5 JP2007503030A JP2007503030A JP2007528417A5 JP 2007528417 A5 JP2007528417 A5 JP 2007528417A5 JP 2007503030 A JP2007503030 A JP 2007503030A JP 2007503030 A JP2007503030 A JP 2007503030A JP 2007528417 A5 JP2007528417 A5 JP 2007528417A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- ring
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- 125000001072 heteroaryl group Chemical group 0.000 claims 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 45
- 125000003118 aryl group Chemical group 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 39
- 125000004404 heteroalkyl group Chemical group 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 239000001257 hydrogen Substances 0.000 claims 37
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 6
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 5
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55183604P | 2004-03-09 | 2004-03-09 | |
| US60/551,836 | 2004-03-09 | ||
| PCT/US2005/008049 WO2005087769A1 (en) | 2004-03-09 | 2005-03-09 | Fused ring azadecalin glucocorticoid receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007528417A JP2007528417A (ja) | 2007-10-11 |
| JP2007528417A5 true JP2007528417A5 (https=) | 2009-07-09 |
| JP4931794B2 JP4931794B2 (ja) | 2012-05-16 |
Family
ID=34961932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503030A Expired - Fee Related JP4931794B2 (ja) | 2004-03-09 | 2005-03-09 | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7928237B2 (https=) |
| EP (1) | EP1735308B1 (https=) |
| JP (1) | JP4931794B2 (https=) |
| KR (1) | KR101185281B1 (https=) |
| CN (1) | CN101027301B (https=) |
| AT (1) | ATE407934T1 (https=) |
| AU (1) | AU2005222421B2 (https=) |
| CA (1) | CA2558899C (https=) |
| CY (1) | CY1108621T1 (https=) |
| DE (1) | DE602005009687D1 (https=) |
| DK (1) | DK1735308T3 (https=) |
| ES (1) | ES2313317T3 (https=) |
| IL (1) | IL177982A (https=) |
| NZ (1) | NZ550362A (https=) |
| PT (1) | PT1735308E (https=) |
| WO (1) | WO2005087769A1 (https=) |
| ZA (1) | ZA200608306B (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558899C (en) * | 2004-03-09 | 2013-02-05 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| TWI410422B (zh) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
| US20100261693A1 (en) | 2007-10-17 | 2010-10-14 | Ulmann Andre | Method for treating cushing's syndrome |
| EP3607942B1 (en) | 2008-11-07 | 2025-10-01 | University of Sheffield | Medicament and method of diagnosis |
| JP5637568B2 (ja) * | 2009-05-12 | 2014-12-10 | コーセプト セラピューティクス， インコーポレイテッド | 固体形態および調製のためのプロセス |
| EP2493303A4 (en) * | 2009-10-30 | 2013-06-26 | Merck Sharp & Dohme | 2- [1-PHENYL-5-HYDROXY-4A-SUBSTITUTED HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYLPHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
| WO2011087946A1 (en) * | 2010-01-15 | 2011-07-21 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
| CN103080108A (zh) * | 2010-08-27 | 2013-05-01 | 科赛普特治疗公司 | 吡啶基-胺稠合的氮杂萘烷调节剂 |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| US9006568B2 (en) | 2012-02-15 | 2015-04-14 | Phillips 66 Company | Synthesis of photovoltaic conjugated polymers |
| US20130225633A1 (en) * | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| CA2872260C (en) * | 2012-05-25 | 2020-12-22 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2014088795A1 (en) | 2012-12-03 | 2014-06-12 | Phillips 66 Company | Benzo [1,2-b:4,5-b'] dithiophene-thienothiophene based conjugated polymers |
| PL3848027T3 (pl) | 2013-11-25 | 2023-07-24 | Corcept Therapeutics Incorporated | Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego |
| WO2015077537A1 (en) * | 2013-11-25 | 2015-05-28 | Corcept Therapeutics, Inc. | Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators |
| AU2016226451B2 (en) * | 2015-03-02 | 2019-12-19 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors |
| US10610534B2 (en) | 2015-03-30 | 2020-04-07 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| KR20180052120A (ko) | 2015-08-13 | 2018-05-17 | 코어셉트 쎄라퓨틱스, 잉크. | Acth-의존성 쿠싱 증후군을 감별 진단하는 방법 |
| US10418555B2 (en) | 2015-10-01 | 2019-09-17 | Phillips 66 Company | Formation of films for organic photovoltaics |
| US9905769B2 (en) | 2015-10-01 | 2018-02-27 | Phillips 66 Company | Process of manufacturing an electron transport material |
| US10099963B2 (en) | 2015-10-01 | 2018-10-16 | Phillips 66 Company | Formation of films for organic photovoltaics |
| US10312448B2 (en) | 2015-10-01 | 2019-06-04 | Phillips 66 Company | Process of manufacturing an electron transport material |
| US9911919B2 (en) | 2015-10-01 | 2018-03-06 | Phillips 66 Company | Process of manufacturing an electron transport material |
| JP6765443B2 (ja) | 2016-01-19 | 2020-10-07 | コーセプト セラピューティクス， インコーポレイテッド | 異所性クッシング症候群の鑑別診断 |
| WO2017151613A1 (en) | 2016-03-01 | 2017-09-08 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| AU2018230429B2 (en) | 2017-03-09 | 2023-06-15 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
| MX2019011543A (es) * | 2017-03-31 | 2019-12-16 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical. |
| WO2018236749A2 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11464764B2 (en) | 2018-12-19 | 2022-10-11 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| EP4653047A3 (en) | 2019-03-18 | 2026-02-18 | Nieman, Lynnette K. | Mifepristone for use in improving insulin sensitivity |
| AU2020367769B2 (en) | 2019-10-16 | 2023-10-12 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| JP7569492B2 (ja) | 2019-12-11 | 2024-10-18 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| ES3060361T3 (en) | 2019-12-21 | 2026-03-26 | Corcept Therapeutics Inc | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| BR112022015011A2 (pt) | 2020-01-29 | 2022-09-20 | Corcept Therapeutics Inc | Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical |
| AU2021220763B2 (en) * | 2020-02-10 | 2024-01-18 | Corcept Therapeutics Incorporated | Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator |
| WO2021242912A1 (en) | 2020-05-27 | 2021-12-02 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 |
| CN116113627B (zh) | 2020-06-22 | 2025-06-03 | 科赛普特治疗公司 | 季吲哚糖皮质激素受体拮抗剂 |
| WO2022081725A1 (en) * | 2020-10-16 | 2022-04-21 | The Scripps Research Institute | Therapeutic uses of glucocorticoids with anabolic effects in skeletal muscle |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| CN114907340A (zh) * | 2021-02-09 | 2022-08-16 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| IL313667A (en) | 2021-12-21 | 2024-08-01 | Corcept Therapeutics Inc | Glucocorticoid receptor antagonists INDAZOL CYCLES |
| CA3243549A1 (en) | 2021-12-21 | 2023-06-29 | Corcept Therapeutics Incorporated | INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS |
| CN119585268A (zh) * | 2022-06-28 | 2025-03-07 | 科赛普特治疗公司 | 制备杂芳基-酮稠合的氮杂萘烷糖皮质激素受体调节剂的方法 |
| CN117510490A (zh) * | 2022-08-03 | 2024-02-06 | 江苏恒瑞医药股份有限公司 | 一种稠合氮杂萘烷类衍生物的晶型及其制备方法 |
| KR20250073629A (ko) | 2022-10-06 | 2025-05-27 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제의 제형 |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| IL322578A (en) * | 2023-02-24 | 2025-10-01 | Corcept Therapeutics Inc | Methods for preparing intermediates of glucocorticoid receptor modulators fused with azedecline-type heteroaryl ketone |
| TW202539687A (zh) * | 2024-01-15 | 2025-10-16 | 香港商英矽智能科技知識產權有限公司 | 作為糖皮質激素受體調節劑的新化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| EP1512683B1 (en) * | 1998-03-10 | 2011-08-31 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| JP4745609B2 (ja) * | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
| CA2558899C (en) * | 2004-03-09 | 2013-02-05 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| JP5637568B2 (ja) * | 2009-05-12 | 2014-12-10 | コーセプト セラピューティクス， インコーポレイテッド | 固体形態および調製のためのプロセス |
-
2005
- 2005-03-09 CA CA2558899A patent/CA2558899C/en not_active Expired - Lifetime
- 2005-03-09 US US10/591,884 patent/US7928237B2/en active Active
- 2005-03-09 JP JP2007503030A patent/JP4931794B2/ja not_active Expired - Fee Related
- 2005-03-09 CN CN2005800114815A patent/CN101027301B/zh not_active Expired - Fee Related
- 2005-03-09 WO PCT/US2005/008049 patent/WO2005087769A1/en not_active Ceased
- 2005-03-09 NZ NZ550362A patent/NZ550362A/en not_active IP Right Cessation
- 2005-03-09 AU AU2005222421A patent/AU2005222421B2/en not_active Ceased
- 2005-03-09 DK DK05725295T patent/DK1735308T3/da active
- 2005-03-09 AT AT05725295T patent/ATE407934T1/de active
- 2005-03-09 DE DE602005009687T patent/DE602005009687D1/de not_active Expired - Lifetime
- 2005-03-09 ES ES05725295T patent/ES2313317T3/es not_active Expired - Lifetime
- 2005-03-09 KR KR1020067020988A patent/KR101185281B1/ko not_active Expired - Fee Related
- 2005-03-09 EP EP05725295A patent/EP1735308B1/en not_active Expired - Lifetime
- 2005-03-09 PT PT05725295T patent/PT1735308E/pt unknown
-
2006
- 2006-09-10 IL IL177982A patent/IL177982A/en active IP Right Grant
- 2006-10-05 ZA ZA200608306A patent/ZA200608306B/xx unknown
-
2008
- 2008-12-05 CY CY20081101413T patent/CY1108621T1/el unknown
-
2011
- 2011-03-11 US US13/046,529 patent/US20110166110A1/en not_active Abandoned
-
2012
- 2012-05-21 US US13/476,776 patent/US8557839B2/en not_active Expired - Fee Related
-
2013
- 2013-09-12 US US14/025,459 patent/US20140179671A1/en not_active Abandoned